Sadia Saleem
Department of Breast Medical Oncology, Division of Cancer Medicine
About Sadia Saleem
Dr. Sadia Saleem completed her residency training in
internal medicine at Baylor College of Medicine in Houston, Texas. She then
completed fellowship in Hematology and Oncology at the University of Texas
Southwestern in Dallas, Texas. She is board certified in both hematology and
oncology. She then joined MD Anderson Cancer Center as faculty. She sees general oncology, benign and malignant hematology patients, and has a
special interest in breast cancer. She is a member of the American
Society of Clinical Oncology and has presented posters at various national
conferences. She is also co-author on several peer reviewed publications.
Other languages spoken Urdu and Hindi.
Read More
Other languages spoken Urdu and Hindi.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2004 | Aga Khan University, Karachi, PK, MBBS in MBBS |
Postgraduate Training
| 2011-2014 | Clinical Fellowship, Hematology Oncology Fellowship, Harold C Simmons Comprehensive Cancer Center/UT Southwestern, Dallas, Texas |
| 2007-2009 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
| 2006-2007 | Clinical Internship, Baylor College of Medicine, Houston, Texas |
Experience & Service
Institutional Committee Activities
Member, Wellness Committee for Breast Medical Oncology Department, 2021 - Present
Section Chief, Breast Medical Oncology for the Houston Area Locations, 2021 - Present
Member, Member of the Breast Service Line expansion effort for strategic Reopening and Flexible recovery, 2020 - Present
Leader, Houston Area Locations-Texas Medical Center Inflammatory Breast Cancer Collaboration, 2020 - Present
Leader, Inflammatory Breast Cancer Program at the Houston Area Locations, in collaboration with the Morgan Welch Inflammatory breast cancer Center MDACC, 2020 - Present
Member, Senate Faculty welfare Sub committee, 2019 - Present
Senator for Breast Medical Oncology, Faculty Senate for MD Anderson Cancer Center, 2019 - Present
Member, Member of Sugar Land Houston Area Location Ambulatory Treatment Center Performance Improvement Project, 2019 - 2020
Member, Sugar Land Patient Committee, 2019 - Present
Member, Houston Area Locations clinical research steering committee, 2019 - 2020
Member, Breast Medical Oncology clinical trial subgroup for the Houston Area Locations, 2015 - 2020
Member, Member of the Remote Consenting Initiative, 2010 - 2019
Honors & Awards
| 2022 - 2023 | Multi-Year Appointment Award |
| 2021 - 2023 | Top Performer 1% nationally on CAHPS measures |
| 2019 | Top Performer 10% nationally on CAHPS measures |
| 2013 | Rooney Cancer Award, Harold C. Simmons Cancer Center/UT Southwestern |
| 2000 - 2004 | Begum Shafiqa Zia Scholarship, Aga Khan University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
- Nakhlis F, Niman SM, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Carisa Le-Petross HT, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan M, Lynce F, Layman RM. Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer. Breast Cancer Res Treat 204(2):289-297, 2024. e-Pub 2024. PMID: 38155272.
- Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
- Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Ileana Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. e-Pub 2023. PMID: 37016732.
- Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
- Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
- Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
- Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 29:1-12, 2021. e-Pub 2021. PMID: 33842000.
- Chainitikun S, Espinosa Fernandez JR, Long JP, Iwase T, Kida K, Wang X, Saleem S, Lim B, Valero V, Ueno NT. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One 16(4):e0250057, 2021. e-Pub 2021. PMID: 33861773.
Abstracts
- Saleem S. Phase Ib Study of Selinexor and Eribulin Combination in Advanced Solid Tumors and Triple Negative Breast Cancer. Clinical Trials, 2022. e-Pub 2022.
- Westin SN, Litton J, Williams R, Shepherd CJ, Brugger W, Pease EJ, Soliman P, Frumovitz M, Levenback C, Sood A, Moulder S, Valero V, Saleem S, Rodriguez A, Cyriac A, Engerman L, Samuel C, Mills G, Coleman R. Phase 1 trial off olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
Selected Presentations & Talks
Regional Presentations
- 2017. Speaker, Breast Friends - Role of diet and lifestyle on Breast Cancer Survivorship. Conference. Breast Friend Sugar Land Support group. Sugar Land, US.
- 2017. Managing the side effects of Breast Cancer Treatment: Role of Integrative Medicine & Beyond, Breast Friends Support Group and Educational Program. Conference. Breast Friends Support Group Sugar Land, US.
- 2016. Overview of Breast Cancer Chemotherapy, MD Anderson Sugar Land Monthly Meeting. Conference. MD Anderson Sugar Land, US.
- 2016. Improving Outcomes in Triple Negative Breast Cancer using Molecular Triage & Diagnostic Imaging to guide Neoadjuvant Therapy, Sugar Land Educational Series Seminar. Conference. MD Anderson Sugar Land, US.
- 2016. Novel Anti-Her 2 Therapies for Breast Cancer, Sugar Land Educational series seminar. Conference. MD Anderson Sugar Land, US.
National Presentations
- 2013. A case of bendamustine induced eosinophilic pneumonitis. Conference. Annual Chest Conference. Chicago, IL, US.
- 2013. Acute Fibrinous and Organizing Pneumonia: A Rare Histopathologic Variant of Bleomycin-induced Lung Injury. Conference. Annual Chest Conference. Chicago, IL, US.
- 2008. Primary Effusion Lymphoma in an HIV positive man. Conference. Oral Presentation: Society of General Internal Medicine. New Orleans, LA, US.
International Presentations
- 2022. Locoregional Nodal Status at Initial Presentation on Ultrasound and PET/CT of Inflammatory Breast Cancer Patients is Predictive of Overall Survival. Invited. International Inflammatory Breast Cancer Symposium. Houston, US.
- 2018. Oral Presentation by Dr. Shannon Westin:Phase 1 trial of Olaparib (PARP inhibitor) and Vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. Conference. ASCO Annual Meeting. Chicago, US.
- 2014. Association of Adiponectin in patatin-like phospholipase domain-containing 3 (PNPLA3) associated hepatic steatosis. Conference. ASCO GI Cancers Symposium, US.
- 2013. Piasma Adiponectin to predict incident cancer in a large multiethnic population-based cohort study. Conference. ASCO Annual Meeting. Chicago, US.
Patient Reviews
CV information above last modified May 07, 2025